The addition of tezepelumab to subcutaneous allergen immunotherapy for 1 year improved results in nasal allergen challenges for patients with cat allergies, according to a study published in The Journal of Allergy and Clinical Immunology.
Patients who used both tezepelumab (Tezspire, Amgen/AstraZeneca), a human monoclonal anti-thymic stromal lymphopoietin antibody, and subcutaneous allergen immunotherapy (SCIT) also experienced reductions in peak nasal symptoms a full year after treatment had stopped, whereas those results did not persist among patients who only received immunotherapy, the